Innovations for Next-Generation Antibody-Drug Conjugates (eBook)
VIII, 357 Seiten
Springer International Publishing (Verlag)
978-3-319-78154-9 (ISBN)
Antibody-drug conjugates (ADCs) stand at the verge of a transformation. Scores of clinical programs have yielded only a few regulatory approvals, but a wave of technological innovation now empowers us to overcome past technical challenges. This volume focuses on the next generation of ADCs and the innovations that will enable them. The book inspires the future by integrating the field's history with novel strategies and cutting-edge technologies. While the book primarily addresses ADCs for solid tumors, the last chapter explores the emerging interest in using ADCs to treat other diseases.
The therapeutic rationale of ADCs is strong: to direct small molecules to the desired site of action (and away from normal tissues) by conjugation to antibodies or other targeting moieties. However, the combination of small and large molecules imposes deep complexity to lead optimization, pharmacokinetics, toxicology, analytics and manufacturing. The field has made significant advances in all of these areas by improving target selection, ADC design, manufacturing methods and clinical strategies. These innovations will inspire and educate scientists who are designing next-generation ADCs with the potential to transform the lives of patients.
Marc Damelin is Senior Director, Biology at Mersana Therapeutics in Cambridge, Massachusetts. His group is responsible for the discovery of therapeutic ADCs enabled by Mersana's proprietary linker-payload-scaffold technologies. Prior, Marc spent 10 years at Pfizer Inc. in the Oncology Research Unit, where he led ADC discovery teams and ultimately oversaw the ADC portfolio. He received his Ph.D. in Biophysics from Harvard University and conducted postdoctoral research at Columbia University Medical School as a Fellow of the Damon Runyon Cancer Research Foundation.
Marc Damelin is Senior Director, Biology at Mersana Therapeutics in Cambridge, Massachusetts. His group is responsible for the discovery of therapeutic ADCs enabled by Mersana's proprietary linker-payload-scaffold technologies. Prior, Marc spent 10 years at Pfizer Inc. in the Oncology Research Unit, where he led ADC discovery teams and ultimately oversaw the ADC portfolio. He received his Ph.D. in Biophysics from Harvard University and conducted postdoctoral research at Columbia University Medical School as a Fellow of the Damon Runyon Cancer Research Foundation.
Chapter 1. “Introduction: Motivations for Next-Generation ADCs” -Marc Damelin
Chapter 2. “Combining ADCs with Immuno-oncology Agents” -- Philipp Müller, Jonathan Rios-Doria, Jay Harper and Anthony Cao
Chapter 3. “Improving the Safety Profile of ADCs” -- MagaliGuffroy, HadiFalahatpisheh and Martin Finkelstein
Chapter 4. “Utility of PK-PD Modeling and Simulation to Improve Decision Making for Antibody-Drug Conjugate Development” -- Aman P. Singh and Dhaval K. Shah
Chapter 5.“Regulatory Considerations and Companion Diagnostics” – Elizabeth VanAlphen and Omar Perez
Chapter 6. “ADC Process Development and Manufacturing” – Olivier Marcq
Chapter 7. “HER2-Targeted ADCs: At the forefront of ADC technology development” – Kevin J. Hamblett
Chapter 8. “Next generation payloads for ADCs” – L. Nathan Tumey
Chapter 9.“Delivering more payload: High DAR ADCs” - Natalya Bodyak and Alexander V.Yurkovetskiy
Chapter 10.“Site-Specific Antibody Drug Conjugates” – Feng Tian, Dowdy Jackson and Yun Bai
Chapter 11. “Bispecific and Biparatopic Antibody-Drug Conjugates” -- Frank Comer, Changshou Gao and Steve Coats
Chapter 12. “Targeting drug conjugates to the tumor microenvironment: Probody Drug Conjugates” -- Jack Lin and Jason Sagert
Chapter 13.“Antibody-Drug Conjugates: Targeting the Tumor Microenvironment” – Alberto Dal Corso, SamueleCazzamalli and Dario Neri
Chapter 14. “Next Horizons: ADCs Beyond Oncology” -- Shan Yu, Andrew Lim and Matthew S. Tremblay
| Erscheint lt. Verlag | 29.5.2018 |
|---|---|
| Reihe/Serie | Cancer Drug Discovery and Development | Cancer Drug Discovery and Development |
| Zusatzinfo | VIII, 357 p. 70 illus., 52 illus. in color. |
| Verlagsort | Cham |
| Sprache | englisch |
| Themenwelt | Medizin / Pharmazie ► Studium |
| Naturwissenschaften ► Biologie | |
| Schlagworte | antibody-drug conjugates • Conjugation • Immuno-Oncology • Oncology • pharmacokinetics, |
| ISBN-10 | 3-319-78154-5 / 3319781545 |
| ISBN-13 | 978-3-319-78154-9 / 9783319781549 |
| Haben Sie eine Frage zum Produkt? |
PDF (Wasserzeichen)Größe: 10,5 MB
DRM: Digitales Wasserzeichen
Dieses eBook enthält ein digitales Wasserzeichen und ist damit für Sie personalisiert. Bei einer missbräuchlichen Weitergabe des eBooks an Dritte ist eine Rückverfolgung an die Quelle möglich.
Dateiformat: PDF (Portable Document Format)
Mit einem festen Seitenlayout eignet sich die PDF besonders für Fachbücher mit Spalten, Tabellen und Abbildungen. Eine PDF kann auf fast allen Geräten angezeigt werden, ist aber für kleine Displays (Smartphone, eReader) nur eingeschränkt geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen dafür einen PDF-Viewer - z.B. den Adobe Reader oder Adobe Digital Editions.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen dafür einen PDF-Viewer - z.B. die kostenlose Adobe Digital Editions-App.
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich
